Approval of Retifanlimab for Advanced Anal Cancer Treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for retifanlimab, marketed as ZYNYZ, to be used in the treatment of adults suffering from squamous cell carcinoma of the anal canal (SCAC). This particular form of anal cancer is characterised by its inability to be surgically removed and may either be metastatic or have recurred in the original site.
This recent approval follows an earlier endorsement on 6 July 2026, when retifanlimab was also authorised for the treatment of adults with advanced Merkel cell carcinoma (MCC), a rare and aggressive variant of skin cancer.
Mechanism and Administration of Retifanlimab
Retifanlimab is administered in conjunction with chemotherapy agents carboplatin and paclitaxel. This combination works by enhancing the body’s immune response to cancer cells. Specifically, retifanlimab inhibits a pathway that cancer cells exploit to evade detection by the immune system, thereby allowing immune cells to more effectively identify and eliminate these malignant cells.
The drug is delivered through an intravenous infusion lasting approximately 30 minutes, scheduled once every four weeks. For the initial six cycles of treatment, it is combined with carboplatin and paclitaxel.
Clinical Study Results and Efficacy
A clinical study involving 308 participants diagnosed with metastatic or locally advanced SCAC demonstrated that the use of retifanlimab alongside chemotherapy was significantly more effective than a placebo in extending the duration of time patients lived without disease progression.
For further details regarding side effects associated with this medication, individuals are advised to consult Section 4 of the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC) available through the MHRA’s official resources.
Ongoing Monitoring and Regulatory Oversight
Julian Beach, Executive Director of Operations at the MHRA, highlighted the importance of providing thoroughly evaluated treatment options for those living with advanced anal cancer. He reaffirmed the agency’s commitment to monitoring the safety and effectiveness of retifanlimab as its use becomes more widespread.
This approval was officially granted on 5 November 2026 to Incyte Biosciences UK Ltd and was processed through the International Recognition Procedure (IRP).
The Role of MHRA in Healthcare Regulation
The MHRA is the regulatory authority overseeing all medications and medical devices in the UK, ensuring their efficacy and safety. The agency’s operations are founded on rigorous, evidence-based assessments to ascertain that the therapeutic benefits outweigh any potential risks. It functions as an executive agency within the Department of Health and Social Care.